|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 39/395 | |
| A61P 35/00 | |||
| G01N 33/574 | |||
| C07K 16/28 | |||
| C07K 16/30 |
| (11) | Patento numeris | 3180025 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 15754347.1 |
| Europos patento paraiškos padavimo data | 2015-08-11 | |
| (97) | Europos patento paraiškos paskelbimo data | 2017-06-21 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-02-26 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2015/044632 |
| Data | 2015-08-11 |
| (87) | Numeris | WO 2016/025464 |
| Data | 2016-02-18 |
| (30) | Numeris | Data | Šalis |
| 201462037848 P | 2014-08-15 | US |
| (72) |
ABADA, Paolo Benjamin, US
CHANG, Shao-Chun, US
HSU, Yanzhi, US
YANG, Ling, US
|
| (73) |
Imclone, LLC,
Eli Lilly and Company Lilly Corporate Center, Indianapolis, Indiana 46285,
US
|
| (54) | ANTI-VEGFR2 ANTIBODY THERAPY FOR HEPATOCELLULAR CARCINOMA |
| ANTI-VEGFR2 ANTIBODY THERAPY FOR HEPATOCELLULAR CARCINOMA |